Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody

Rituximab therapy for B cell chronic lymphocytic leukemia (B-CLL) has met with mixed success. Among several factors to which resistance can be attributed is failure to activate complement dependent cytotoxicity (CDC) due to protective complement regulatory proteins, including the soluble regulator c...

Descripción completa

Detalles Bibliográficos
Autores principales: Winkler, Mark T., Bushey, Ryan T., Gottlin, Elizabeth B., Campa, Michael J., Guadalupe, Eross S., Volkheimer, Alicia D., Weinberg, J. Brice, Patz, Edward F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489178/
https://www.ncbi.nlm.nih.gov/pubmed/28658265
http://dx.doi.org/10.1371/journal.pone.0179841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489178/
https://www.ncbi.nlm.nih.gov/pubmed/28658265
http://dx.doi.org/10.1371/journal.pone.0179841

Ejemplares similares